Krebs Biochemicals and Industries Limited
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various produ… Read more
Krebs Biochemicals and Industries Limited (KREBSBIO) - Net Assets
Latest net assets as of December 2025: ₹-1.61 Billion INR
Based on the latest financial reports, Krebs Biochemicals and Industries Limited (KREBSBIO) has net assets worth ₹-1.61 Billion INR as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹1.66 Billion) and total liabilities (₹3.27 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹-1.61 Billion |
| % of Total Assets | -96.94% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -1223.74% |
| Growth Volatility | 424.55 |
Krebs Biochemicals and Industries Limited - Net Assets Trend (2006–2025)
This chart illustrates how Krebs Biochemicals and Industries Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Krebs Biochemicals and Industries Limited (2006–2025)
The table below shows the annual net assets of Krebs Biochemicals and Industries Limited from 2006 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹-1.46 Billion | -22.67% |
| 2024-03-31 | ₹-1.19 Billion | -19.86% |
| 2023-03-31 | ₹-994.62 Million | -32.45% |
| 2022-03-31 | ₹-750.93 Million | -75.73% |
| 2021-03-31 | ₹-427.33 Million | -70.96% |
| 2020-03-31 | ₹-249.96 Million | -74.93% |
| 2019-03-31 | ₹-142.89 Million | +19.63% |
| 2018-03-31 | ₹-177.79 Million | -1303.82% |
| 2017-03-31 | ₹14.77 Million | -88.65% |
| 2016-03-31 | ₹130.14 Million | -55.64% |
| 2015-03-31 | ₹293.34 Million | +714.41% |
| 2014-03-31 | ₹36.02 Million | -54.68% |
| 2013-03-31 | ₹79.48 Million | -65.67% |
| 2012-03-31 | ₹231.51 Million | -42.96% |
| 2011-03-31 | ₹405.89 Million | -16.50% |
| 2010-03-31 | ₹486.10 Million | -60.90% |
| 2009-03-31 | ₹1.24 Billion | +36.54% |
| 2008-03-31 | ₹910.46 Million | -0.16% |
| 2007-03-31 | ₹911.90 Million | +3.14% |
| 2006-03-31 | ₹884.15 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Krebs Biochemicals and Industries Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 285151832000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹215.61 Million | % |
| Other Comprehensive Income | ₹114.45 Million | % |
| Other Components | ₹1.18 Billion | % |
| Total Equity | ₹-1.46 Billion | 100.00% |
Krebs Biochemicals and Industries Limited Competitors by Market Cap
The table below lists competitors of Krebs Biochemicals and Industries Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Celebrity Fashions Limited
NSE:CELEBRITY
|
$2.27 Million |
|
Lichen China Limited Class A Ordinary Shares
NASDAQ:LICN
|
$2.27 Million |
|
Geekco Technologies Corp
V:GKO
|
$2.27 Million |
|
Sacgasco Limited
PINK:SGCSF
|
$2.27 Million |
|
Silynxcom Ltd.
NYSE MKT:SYNX
|
$2.27 Million |
|
Hagag Europe Development ZF Ltd
TA:HGGE
|
$2.27 Million |
|
NexPoint Hospitality Trust
V:NHT-U
|
$2.27 Million |
|
Vivic Corp
OTCQB:VIVC
|
$2.27 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Krebs Biochemicals and Industries Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,192,167,000 to -1,462,388,000, a change of -270,221,000.
- Net loss of 269,393,000 reduced equity.
- Other comprehensive income decreased equity by 1.
- Other factors decreased equity by 827,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹-269.39 Million | -18.42% |
| Other Comprehensive Income | ₹-1.00 | -0.0% |
| Other Changes | ₹-828.00K | -0.06% |
| Total Change | ₹- | % |
Book Value vs Market Value Analysis
This analysis compares Krebs Biochemicals and Industries Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-03-31 | ₹142.31 | ₹48.33 | x |
| 2007-03-31 | ₹144.67 | ₹48.33 | x |
| 2008-03-31 | ₹124.72 | ₹48.33 | x |
| 2009-03-31 | ₹147.97 | ₹48.33 | x |
| 2010-03-31 | ₹51.87 | ₹48.33 | x |
| 2011-03-31 | ₹43.31 | ₹48.33 | x |
| 2012-03-31 | ₹23.50 | ₹48.33 | x |
| 2013-03-31 | ₹8.07 | ₹48.33 | x |
| 2015-03-31 | ₹22.98 | ₹48.33 | x |
| 2016-03-31 | ₹9.62 | ₹48.33 | x |
| 2017-03-31 | ₹1.04 | ₹48.33 | x |
| 2018-03-31 | ₹-12.94 | ₹48.33 | x |
| 2019-03-31 | ₹-8.59 | ₹48.33 | x |
| 2020-03-31 | ₹-13.89 | ₹48.33 | x |
| 2021-03-31 | ₹-21.78 | ₹48.33 | x |
| 2022-03-31 | ₹-34.83 | ₹48.33 | x |
| 2023-03-31 | ₹-46.13 | ₹48.33 | x |
| 2024-03-31 | ₹-55.29 | ₹48.33 | x |
| 2025-03-31 | ₹-67.84 | ₹48.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Krebs Biochemicals and Industries Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -62.20%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-80.27%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -16.11% | -50.00% | 0.12x | 2.63x | ₹-230.83 Million |
| 2007 | -8.41% | -16.22% | 0.22x | 2.33x | ₹-167.89 Million |
| 2008 | -11.19% | -20.10% | 0.25x | 2.20x | ₹-192.94 Million |
| 2009 | -34.29% | -83.26% | 0.21x | 1.97x | ₹-550.59 Million |
| 2010 | -11.66% | -12.26% | 0.29x | 3.30x | ₹-105.29 Million |
| 2011 | -16.46% | -9.22% | 0.46x | 3.86x | ₹-107.41 Million |
| 2012 | -75.32% | -24.64% | 0.48x | 6.42x | ₹-197.53 Million |
| 2013 | -131.61% | -75.42% | 0.10x | 17.32x | ₹-112.55 Million |
| 2014 | -67.79% | 0.00% | 0.00x | 38.25x | ₹-28.02 Million |
| 2015 | -20.45% | -53556.25% | 0.00x | 4.07x | ₹-89.32 Million |
| 2016 | -125.41% | -1265.54% | 0.01x | 8.95x | ₹-176.22 Million |
| 2017 | -1086.70% | -946.70% | 0.01x | 82.66x | ₹-161.97 Million |
| 2018 | 0.00% | -70.15% | 0.20x | 0.00x | ₹-160.47 Million |
| 2019 | 0.00% | -53.89% | 0.26x | 0.00x | ₹-185.83 Million |
| 2020 | 0.00% | -122.42% | 0.18x | 0.00x | ₹-263.72 Million |
| 2021 | 0.00% | -73.46% | 0.24x | 0.00x | ₹-240.85 Million |
| 2022 | 0.00% | -74.58% | 0.31x | 0.00x | ₹-370.17 Million |
| 2023 | 0.00% | -47.36% | 0.30x | 0.00x | ₹-147.46 Million |
| 2024 | 0.00% | -39.13% | 0.28x | 0.00x | ₹-78.07 Million |
| 2025 | 0.00% | -62.20% | 0.26x | 0.00x | ₹-123.15 Million |
Industry Comparison
This section compares Krebs Biochemicals and Industries Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Krebs Biochemicals and Industries Limited (KREBSBIO) | ₹-1.61 Billion | -16.11% | N/A | $2.27 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |